Loading…
Hosted by Syneos Health · 🇺🇸 US · EN-US · 14 episodes
Established thought leaders with verified media credentials.
What are the signals today that will define the future of oncology treatment tomorrow? The Syneos Health Podcast: Early Signals brings together leaders across biopharma, healthcare, academia and technology to explore the innovations reshaping drug development in oncology. Hosted by experts across Syneos Health, including Wael Harb, MD, Head of Research and Development and Scientific Strategy in oncology, each episode captures candid conversations about emerging science, evolving market dynamics and the trends poised to influence the future of patient care. Tune in for timely perspectives on what's next—and what it means for the oncology industry, its stakeholders and most importantly its patients. Subscribe to The Syneos Health Podcast: Early Signals for new episodes. If there’s a topic you’d like us to explore, send us a message at podcasts@syneoshealth.com . <p
Syneos Health hosts The Syneos Health Podcast: Early Signals, a business show with 14 episodes published.
Can the next generation of tumor-infiltrating lymphocyte (TIL) therapies overcome the barriers that have limited broader adoption of cell therapy in solid tumors? In this episode of Early Signals, recorded live at ASCO 2
Can minimal residual disease (MRD) do more than measure response? Could it redefine how multiple myeloma therapies are developed, approved and ultimately used to guide patient care? In this episode of Early Signals, reco
Can AI predict cancer's next move before drug resistance develops? Drug resistance remains one of the greatest challenges in oncology drug development. Most targeted therapies are designed to treat today's tumor biology,
What if artificial intelligence could help remove the uncertainty from cancer treatment decisions? Precision oncology has already transformed cancer care by matching therapies to actionable biomarkers, but today's advanc
Less than 5% of patients participate in clinical trials today; a statistic that has remained virtually unchanged for more than two decades despite massive advances in science and technology. In this episode of Early Sign
Antibody-drug conjugates (ADCs) are transforming oncology, but scientific innovation alone isn't enough. As platforms become more sophisticated—with novel linker technologies, diversified payloads and increasingly target
What happens when an established treatment regains its effectiveness against resistant disease? In this episode of the Syneos Health Podcast: Early Signals, Wael Harb, MD, Head of R&D and Scientific Strategy in Oncology
Can MYC finally be drugged? Learn how MycRx is advancing a direct MYC inhibitor and navigating the science and business of oncology innovation. What if one of cancer's most important drivers was no longer considered "und
What are the signals today that will define the future of oncology treatment tomorrow? The Syneos Health Podcast: Early Signals brings together leaders across biopharma, healthcare, academia and technology to explore the
We continue our Project Optimus series with a focus on clinical pharmacology —a foundational element in redefining dose optimization in oncology drug development. Dr. Wael Harb is joined by Pierre-Olivier Tremblay , Vice
As regulatory expectations evolve under the FDA’s Project Optimus oncology dosing initiative, biostatistics is emerging as a central pillar in designing and executing trials that move beyond the traditional maximum toler
In this episode, we continue our exploration of Project Optimus and the evolution of dose optimization in oncology drug development. Following our discussion on regulatory expectations in the previous episode, we now tur
In this episode, Dr. Wael Harb , Vice President of Medical Management at Syneos Health, continues the exploration of FDA's groundbreaking Project Optimus and its profound implications for oncology drug development. He is
Launched in 2021 by the FDA's Oncology Center of Excellence, Project Optimus seeks to reshape traditional oncology trial designs and dosing paradigms, shifting from maximum tolerated doses to precision dosing strategies.
Dr. Samer Al Hadidi
University of Texas Southwestern
1 appearance on this show
Diana Chen
MediLink Therapeutics
1 appearance on this show
Jason Litten
Genelux
1 appearance on this show
Wael Harb
Syneos Health
1 appearance on this show
Pierre-Olivier Tremblay
Syneos Health
1 appearance on this show
X.Q Xue
Syneos Health
1 appearance on this show
Patrick Melvin
Syneos Health
1 appearance on this show
Dr. Wael Harb
Syneos Health
2 appearances on this show
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
The Syneos Health Podcast: Early Signals has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their business audience.
The Syneos Health Podcast: Early Signals is hosted by Syneos Health. The show is categorised under business (management) and has published 14 episodes.
The Syneos Health Podcast: Early Signals has published 14 episodes.
The Syneos Health Podcast: Early Signals regularly covers business, management. It sits in the business category, with a management focus.
The Syneos Health Podcast: Early Signals is accessible for guests with genuine business expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The Syneos Health Podcast: Early Signals hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The Syneos Health Podcast: Early Signals average 22 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The Syneos Health Podcast: Early Signals's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 4 days ago.